QUIDELORTHO CORP Net Income (Loss) Available to Common Stockholders, Diluted
QUIDELORTHO CORP (QDEL) reported Net Income (Loss) Available to Common Stockholders, Diluted of $548.70 million for the 12-month period ending 2023-01-01, per its 10-K filed 2023-02-23.
Discontinued › Income Statement
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2023-02-23
- QUIDELORTHO CORP net income (loss) available to common stockholders, diluted for fiscal 2023 was $548.70M, a 22.08% decline from fiscal 2022.
- QUIDELORTHO CORP net income (loss) available to common stockholders, diluted for fiscal 2022 was $704.20M, a 13.14% decline from fiscal 2021.
- QUIDELORTHO CORP net income (loss) available to common stockholders, diluted for fiscal 2021 was $810.70M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|
| 2023-01-01 | $548.70M 10-K · filed 2023-02-23 |
| 2022-01-02 | $704.20M 10-K · filed 2023-02-23 |
| 2021-01-03 | $810.70M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |